UniProt P41182
B-cell lymphoma 6 protein (P41182)
B-cell lymphoma 6 protein (UniProt P41182): 128 experimental structures and 1 predicted model on GenesisL1, 78 ligands bound, 8 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.
- UniProt
- P41182
- Protein
- B-cell lymphoma 6 protein
- Experimental structures
- 128
- Predicted models
- 1
- Ligands
- 78
- Pockets
- 8 · 1 record with a druggable one
Structures
129 records of P41182 in the MolNFT archive: 128 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1R28 | Crystal Structure of the B-Cell Lymphoma 6 (BCL6) BTB domain to 2.2 Angstrom | x-ray diffraction | A, B | — | — |
| 1R28 | Crystal structure of the B-cell lymphoma 6 (BCL6) btb domain to 2.2 ångström | x-ray diffraction | A, B | — | — |
| 1R29 | Crystal Structure of the B-Cell Lymphoma 6 (BCL6) BTB Domain to 1.3 Angstrom | x-ray diffraction | A | — | — |
| 1R29 | Crystal structure of the B-cell lymphoma 6 (BCL6) btb domain to 1.3 ångström | x-ray diffraction | A | — | — |
| 1R2B | Crystal structure of the BCL6 BTB domain complexed with a SMRT co-repressor peptide | x-ray diffraction | A, B | — | — |
| 1R2B | Crystal structure of the BCL6 btb domain complexed with a smrt co- repressor peptide | x-ray diffraction | A, B | — | — |
| 2EN2 | Solution structure of the C2H2 type zinc finger (region 598-626) of human B-cell lymphoma 6 protein | solution nmr | A | — | — |
| 2EN2 | Solution structure of the C2H2 type zinc finger (region 598-626) of human B-cell lymphoma 6 protein | solution nmr | A | — | — |
| 2EOS | Solution structure of the C2H2 type zinc finger (region 626-654) of human B-cell lymphoma 6 protein | solution nmr | A | — | — |
| 2EOS | Solution structure of the C2H2 type zinc finger (region 626-654) of human B-cell lymphoma 6 protein | solution nmr | A | — | — |
| 2LCE | Chemical shift assignment of Hr4436B from Homo Sapiens, Northeast Structural Genomics Consortium | solution nmr | A | — | — |
| 2LCE | Chemical shift assignment of HR4436B from homo sapiens, northeast structural genomics consortium | solution nmr | A | — | — |
| 2YRM | Solution structure of the 1st zf-C2H2 domain from Human B-cell lymphoma 6 protein | solution nmr | A | — | — |
| 2YRM | Solution structure of the 1ST zf-C2H2 domain from human B-cell lymphoma 6 protein | solution nmr | A | — | — |
| 3BIM | Crystal structure of the BCL6 BTB domain dimer in complex with the BCOR BBD corepressor peptide | x-ray diffraction | A, B, C, D, E, F, G, H | — | — |
| 3BIM | Crystal structure of the BCL6 btb domain dimer in complex with the bcor bbd corepressor peptide | x-ray diffraction | A, B, C, D, E, F, G, H | — | — |
| 3E4U | Crystal Structure of the Wild-Type Human BCL6 BTB/POZ Domain | x-ray diffraction | A, B, C, D, E, F | — | — |
| 3E4U | Crystal structure of the wild-type human BCL6 BTB/POZ domain | x-ray diffraction | A, B, C, D, E, F | — | — |
| 3LBZ | Crystal Structure of the BCL6 BTB domain complexed with the small molecule inhibitor 79-6 | x-ray diffraction | A, B | — | — |
| 3LBZ | Crystal structure of the BCL6 btb domain complexed with the small molecule inhibitor 79-6 | x-ray diffraction | A, B | — | — |
| 4CP3 | The structure of BCL6 BTB (POZ) domain in complex with the ansamycin antibiotic rifabutin. | x-ray diffraction | A, B | — | — |
| 4CP3 | The structure of BCL6 btb (poz) domain in complex with the ansamycin antibiotic rifabutin. | x-ray diffraction | A, B | — | — |
| 4U2M | Crystal structure of a complex of the Miz1- and BCL6 POZ domains. | x-ray diffraction | A, B, C, D | — | — |
| 4U2M | Crystal structure of a complex of the MIZ1- and BCL6 poz domains. | x-ray diffraction | A, B, C, D | — | — |
| 5H7G | Crystal structure of the BCL6 btb domain in complex with F1324 | x-ray diffraction | A, B | — | — |
| 5H7H | Crystal structure of the BCL6 btb domain in complex with F1324(10-13) | x-ray diffraction | A | — | — |
| 5MW2 | CRYSTAL STRUCTURE OF BCL-6 BTB-domain with BI-3802 | x-ray diffraction | A | U52 | — |
| 5MW2 | Crystal structure of BCL-6 btb-domain with bi-3802 | x-ray diffraction | A | U52 | — |
| 5MW6 | Crystal structure of the BCL6 BTB-domain with compound 1 | x-ray diffraction | A, B | RC0 | — |
| 5MW6 | Crystal structure of the BCL6 btb-domain with compound 1 | x-ray diffraction | A, B | RC0 | — |
| 5MWD | Crystal structure of the BCL6 BTB-domain with compound 2 | x-ray diffraction | A | TJ3 | — |
| 5MWD | Crystal structure of the BCL6 btb-domain with compound 2 | x-ray diffraction | A | TJ3 | — |
| 5N1X | Crystal structure of the BCL6 btb domain in complex with pyrazolo- pyrimidine ligand | x-ray diffraction | A, B, C, D | 8HH | — |
| 5N1Z | Crystal structure of the BCL6 btb domain in complex with pyrazolo- pyrimidine macrocyclic ligand | x-ray diffraction | A | CL, 8GQ | — |
| 5N20 | Crystal structure of the BCL6 BTB domain in complex with pyrazolo-pyrimidine ligand | x-ray diffraction | A | 8GN | — |
| 5N20 | Crystal structure of the BCL6 btb domain in complex with pyrazolo- pyrimidine ligand | x-ray diffraction | A | 8GN | — |
| 5N21 | Crystal structure of the BCL6 btb domain in complex with pyrazolo- pyrimidine ligand | x-ray diffraction | A, B | CL, 8HN | — |
| 5X4M | Crystal structure of the BCL6 btb domain in complex with compound 1 | x-ray diffraction | A | 7ZF | — |
| 5X4N | Crystal structure of the BCL6 btb domain in complex with compound 4 | x-ray diffraction | A | 7ZL | — |
| 5X4O | Crystal structure of the BCL6 btb domain in complex with compound 5 | x-ray diffraction | A | YAM | — |
| 5X4P | Crystal structure of the BCL6 BTB domain in complex with Compound 6 | x-ray diffraction | A | 7ZO | — |
| 5X4P | Crystal structure of the BCL6 btb domain in complex with compound 6 | x-ray diffraction | A | 7ZO | — |
| 5X4Q | Crystal structure of the BCL6 btb domain in complex with compound 7 | x-ray diffraction | A | 7Z6, K | — |
| 5X9O | Crystal structure of the BCL6 btb domain in complex with compound 1A | x-ray diffraction | A | 80R, K | — |
| 5X9P | Crystal structure of the BCL6 btb domain in complex with compound 5 | x-ray diffraction | A | 80L | — |
| 6C3L | Crystal structure of BCL6 BTB domain with compound 15f | x-ray diffraction | A, B | — | — |
| 6C3L | Crystal structure of BCL6 btb domain with compound 15F | x-ray diffraction | A, B | — | — |
| 6C3N | Crystal structure of BCL6 btb domain in complex with compound 7CC5 | x-ray diffraction | A, B | EHY | — |
| 6CQ1 | BCL6 btb domain in complex with 15A | x-ray diffraction | A, B | — | — |
| 6EW6 | Crystal structure of the BCL6 btb domain in complex with anilinopyrimidine ligand | x-ray diffraction | A | C0H | — |
| 6EW7 | Crystal structure of the BCL6 BTB domain in complex with anilinopyrimidine ligand | x-ray diffraction | A, B | CL, C1W | 3 (best 0.48) |
| 6EW7 | Crystal structure of the BCL6 btb domain in complex with anilinopyrimidine ligand | x-ray diffraction | A, B | CL, C1W | — |
| 6EW8 | Crystal structure of the BCL6 BTB domain in complex with anilinopyrimidine ligand | x-ray diffraction | A | CL, C0Q | — |
| 6EW8 | Crystal structure of the BCL6 btb domain in complex with anilinopyrimidine ligand | x-ray diffraction | A | CL, C0Q | — |
| 6TBT | Crystal structure of the BCL6 btb domain in complex with an APT48 peptide | x-ray diffraction | A, B | CL, MG, NA | — |
| 6TCJ | Crystal structure of the BCL6 btb domain in complex with a hybrid btb- binding (hbp) peptide | x-ray diffraction | A, B | NA | — |
| 6TOF | Crystal structure of human BCL6 btb domain in complex with compound 4 | x-ray diffraction | A | NQE | — |
| 6TOG | Crystal structure of human BCL6 btb domain in complex with compound 5 | x-ray diffraction | A | NQH, CL | — |
| 6TOH | Crystal structure of human BCL6 btb domain in complex with compound 6 | x-ray diffraction | A | NQK | — |
| 6TOI | Crystal structure of human BCL6 btb domain in complex with compound 11F | x-ray diffraction | A | NQN | — |
69 records more on the page itself.
Ligands
- CL · Chloride ion · in 45 records
- SO4 · Sulfate ion · in 6 records
- NA · Sodium ion · in 5 records
- U52 · 2-[6-[[5-chloranyl-2-[(3~{S},5~{R})-3,5-dimethylpiperidin-1-yl]pyrimidin-4-yl]amino]-1-methyl-2-oxidanylidene-quinolin-3-yl]oxy-~{N}-methyl-ethanamide · in 3 records
- 7ZO · 5-[(5-chloranylpyrimidin-4-yl)amino]-1,3-dihydroindol-2-one · in 2 records
- 8GN · ~{N}-[5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-[(3~{R})-3-(dimethylamino) pyrrolidin-1-yl]phenyl]ethanamide · in 2 records
- 97S · 2-chloranyl-4-[[4-(ethylamino)-1,3-dimethyl-2-oxidanylidene-quinolin-6-yl]amino]pyridine-3-carbonitrile · in 2 records
- A1ACB · 5-{[5-chloro-2-(methylsulfanyl)pyrimidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one · in 2 records
- A1ACC · (8S)-5-chloro-7-[(2-oxo-2,3-dihydro-1H-indol-5-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile · in 2 records
- A1ACR · 5-[(2,5-dichloropyridin-4-yl)amino]-1,3-dihydro-2H-indol-2-one · in 2 records
- A1ACW · 5-[(2-chloro-5-fluoropyrimidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one · in 2 records
- C0Q · anilinopyrimidine ligand · in 2 records
- C1W · 2-chloranyl-4-[[5-chloranyl-4-[(4-fluorophenyl) amino]pyrimidin-2-yl]amino]benzoic acid · in 2 records
- K · Potassium ion · in 2 records
- NQT · 5-[[5-chloranyl-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]amino]-1-methyl-3-(3-methyl-3-oxidanyl-butyl) benzimidazol-2-one · in 2 records
- NR8 · 2-chloranyl-4-[[1-methyl-3-[(2~{S})-2-oxidanylbutyl]-2-oxidanylidene-benzimidazol-5-yl]amino]pyridine-3-carbonitrile · in 2 records
- RC0 · 5-chloranyl-~{N}-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine · in 2 records
- TEQ · 5-[(5S,7R)-3-fluoranyl-7-(2-methylpyridin-3-yl)-4,5,6, 7-tetrahydropyrazolo[1,5-a]pyrimidin-5-yl]quinolin-2-amine · in 2 records
- TJ3 · 5-[[5-chloranyl-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]amino]-1,3-dihydroindol-2-one · in 2 records
- VH8 · 2-[[6-[(2-chloranyl-3-cyano-pyridin-4-yl)amino]-2-oxidanylidene-1H-quinolin-4-yl]amino]-N-methyl-ethanamide · in 2 records
- VHZ · (2R)-2-[[6-[(2-chloranyl-3-cyano-pyridin-4-yl)amino]-2-oxidanylidene-1H-quinolin-4-yl]amino]-N-methyl-propanamide · in 2 records
- 7R5 · N-(3-chloropyridin-4-yl)-2-[2-(morpholin-4-yl)-4-oxo-3, 4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetamide · in 1 record
- 7RB · 2-[2-(4-benzylpiperidin-1-yl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(3-chloropyridin-4-yl)acetamide · in 1 record
- 7RL · N-(3-chloropyridin-4-yl)-2-(2-{[(2-fluorophenyl)methyl]amino}-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)acetamide · in 1 record
- 7SC · N-(3-chloropyridin-4-yl)-2-{4-oxo-2-[(2-phenylethyl) amino]-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}acetamide · in 1 record
- 7SH · N-(3-chloropyridin-4-yl)-2-{5-(3-cyano-4-hydroxyphenyl)-3-[3-(1-methyl-1H-pyrazol-4-yl)prop-2-yn-1-yl]-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}acetamide · in 1 record
- 7SO · N-(3-chloropyridin-4-yl)-2-{5-(3-cyanophenyl)-3-[3-(1-methyl-1H-pyrazol-4-yl)prop-2-yn-1-yl]-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}acetamide · in 1 record
- 7ST · N-[5-chloro-2-(morpholin-4-yl)pyridin-4-yl]-2-{5-(3-cyano-4-hydroxy-5-methylphenyl)-3-[3-(1-methyl-1H-pyrazol-4-yl)prop-2-yn-1-yl]-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}acetamide · in 1 record
- 7SZ · N-[5-chloro-2-(4-methylpiperazin-1-yl)pyridin-4-yl]-2-{5-(3-cyano-4-hydroxy-5-methylphenyl)-3-[3-(1-methyl-1H-pyrazol-4-yl)prop-2-yn-1-yl]-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}acetamide · in 1 record
- 7Z6 · 5-[[5-chloranyl-2-(pyridin-3-ylmethylamino)pyrimidin-4-yl]amino]-1,3-dihydroindol-2-one · in 1 record
Experiment against prediction
- 2EN2 chain A against the predicted model P41182: TM-score 0.63, RMSD 1.82 Å
- 2EN2 chain A against the predicted model P41182: TM-score 0.63, RMSD 1.82 Å
- 2EOS chain A against the predicted model P41182: TM-score 0.59, RMSD 1.63 Å
- 2EOS chain A against the predicted model P41182: TM-score 0.59, RMSD 1.63 Å
- 2YRM chain A against the predicted model P41182: TM-score 0.58, RMSD 1.99 Å
- 2YRM chain A against the predicted model P41182: TM-score 0.58, RMSD 1.99 Å
- 2LCE chain A against the predicted model P41182: TM-score 0.38, RMSD 3.51 Å
- 2LCE chain A against the predicted model P41182: TM-score 0.38, RMSD 3.51 Å
- 3E4U chain F against the predicted model P41182: TM-score 0.38, RMSD 3.70 Å
- 3E4U chain F against the predicted model P41182: TM-score 0.38, RMSD 3.70 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.